Cargando…

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies

Checkpoint molecules such as programmed death 1 (PD-1) dampen excessive T cell activation to preserve immune homeostasis. PD-1-specific monoclonal antibodies have revolutionized cancer therapy, as they reverse tumour-induced T cell exhaustion and restore CTL activity. Based on this success, decipher...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metzger, Philipp, Kirchleitner, Sabrina V., Koenig, Lars M., Hörth, Christine, Kobold, Sebastian, Endres, Stefan, Schnurr, Max, Duewell, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995819/ https://www.ncbi.nlm.nih.gov/pubmed/29892077 http://dx.doi.org/10.1038/s41598-018-27125-6

Ejemplares similares

Correction to: Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer
por: Metzger, Philipp, et al.
Publicado: (2019)

Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer
por: Metzger, Philipp, et al.
Publicado: (2019)

Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma
por: Duewell, Peter, et al.
Publicado: (2015)

Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model
por: Metzger, Philipp, et al.
Publicado: (2020)

Breaking tumor-induced immunosuppression with 5′-triphosphate siRNA silencing TGFβ and activating RIG-I
por: Schnurr, Max, et al.
Publicado: (2013)

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
por: Koenig, Lars M., et al.
Publicado: (2020)

Monoclonal antibody to intermediate filament antigen cross-reacts with higher plant cells
Publicado: (1985)

P17. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells
por: Schnurr, M, et al.
Publicado: (2014)

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
por: Rataj, Felicitas, et al.
Publicado: (2018)

Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.
por: Boxer, G. M., et al.
Publicado: (1994)

Detection of Bone‐type Alkaline Phosphatase by Monoclonal Antibodies Reacting with Human Osteosarcoma‐associated Antigen
por: Nagoya, Satoshi, et al.
Publicado: (1991)

Two long-lasting human monoclonal antibodies cross-react with monkeypox virus A35 antigen
por: Zhou, Bing, et al.
Publicado: (2023)

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
por: Ruzicka, Michael, et al.
Publicado: (2019)

Monoclonal antibodies specific for T cell-associated carbohydrate determinants react with human blood group antigens CAD and SDA
Publicado: (1988)

Monoclonal antibodies reacting with the MUC2 mucin core protein.
por: Devine, P. L., et al.
Publicado: (1993)

S81. Proffered paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy
por: Grassmann, S, et al.
Publicado: (2014)

THE EFFECT OF CROSS-REACTING ANTIGENS ON THE TOLERANT STATE
por: Cinader, B., et al.
Publicado: (1967)

React and React Native
por: Boduch, Adam
Publicado: (2017)

React and React Native
por: Boduch, Adam
Publicado: (2020)

P10. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
por: Bauer, C, et al.
Publicado: (2014)

Characterization of monoclonal antibodies to Acanthamoeba myosin-I that cross-react with both myosin-II and low molecular mass nuclear proteins
Publicado: (1986)

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
por: Rataj, Felicitas, et al.
Publicado: (2018)

A Monoclonal Antibody against p53 Cross-Reacts with Processing Bodies
por: Thomas, María Gabriela, et al.
Publicado: (2012)

Development of Immunoassay Based on Monoclonal Antibody Reacted with the Neonicotinoid Insecticides Clothianidin and Dinotefuran
por: Uchigashima, Mikiko, et al.
Publicado: (2012)

Monoclonal antibodies to intermediate filament proteins of human cells: unique and cross- reacting antibodies
por: Gown, AM, et al.
Publicado: (1982)

Generation and Characterization of Anti-CD34 Monoclonal Antibodies that React with Hematopoietic Stem Cells
por: Aghebati Maleki, Leili, et al.
Publicado: (2014)

Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
por: Stock, Sophia, et al.
Publicado: (2022)

Volcanic Ash Activates the NLRP3 Inflammasome in Murine and Human Macrophages
por: Damby, David E., et al.
Publicado: (2018)

MRC OX-22, a monoclonal antibody that labels a new subset of T lymphocytes and reacts with the high molecular weight form of the leukocyte-common antigen
Publicado: (1983)

Targeting endogenous nuclear antigens by electrotransfer of monoclonal antibodies in living cells
por: Freund, Guillaume, et al.
Publicado: (2013)

An antigen associated with mesenchyme in human tumours that cross-reacts with brain glycoprotein.
por: Delpech, B., et al.
Publicado: (1979)

Learning React: functional web development with React and Redux
por: Banks, Alex, et al.
Publicado: (2017)

Study of the antigenic cross reactivity between carcinoembryonic antigen and "nonspecific cross reacting antigens" (NCA and NCA 2).
por: Neveu, T., et al.
Publicado: (1975)

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
por: Stoiber, Stefan, et al.
Publicado: (2019)

PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models
por: Lesch, Stefanie, et al.
Publicado: (2022)

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma
por: Wiedemann, Gabriela M, et al.
Publicado: (2018)

React in action
por: Thomas, Mark Tielens
Publicado: (2018)

Introduction to React
por: Gackenheimer, Cory
Publicado: (2015)

Pro React
por: de Sousa Antonio, Cassio
Publicado: (2015)

Learning React
por: Chinnathambi, Kirupa
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t6n64vmv2t7gcj07kr729b4ri5